載入...
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl(T315I) protein has become a potential strategy to overcome drug resistance. Herein, we...
Na minha lista:
| 發表在: | Acta Pharm Sin B |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8148061/ https://ncbi.nlm.nih.gov/pubmed/34094836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.11.009 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|